Project Grant K08HL175235
Award Date
8/1/25
Completion Date
7/31/30
Dollars Obligated
$160K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Nashville, TN 37203, USA
Similar Awards
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), is funding research at Northwestern University to investigate the role of mitochondrial metabolism in alveolar epithelial cell differentiation and the development of lung fibrosis. The $616,000 award, effective September 1, 2024 through August 31, 2029, will support experiments using genetic mouse models to determine how mitochondrial...
This $940,320 Cooperative Agreement awarded by the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), supports a 5-year research project led by Vanderbilt University Medical Center to investigate the molecular mechanisms underlying chronic parenchymal lung diseases like pulmonary fibrosis and bronchopulmonary dysplasia. The project aims to develop a spatially-resolved molecular atlas of chronic lung diseases,...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under CFDA 93.837 - Cardiovascular Diseases Research, provides $1,302,038 to the Regents of the University of Michigan to conduct research on targeting dysfunctional epithelial repair in pulmonary fibrosis. The research aims to elucidate the mediators and pathways that contribute to dysfunctional epithelial phenotypes in persistent lung fibrosis, determine the impact of hypoxia-inducible factor (HIF) signaling...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $740,317 to The Washington University in St. Louis to conduct research on the regulation of alveologenesis, the final phase of lung development, by FGF signaling pathways. The research aims to identify the cellular mechanisms by which FGF signaling regulates cell proliferation, differentiation, and death during the first and second stages...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $123,000 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the University of Chicago to investigate the role of the Hedgehog (HH) signaling pathway in regulating progenitor cell differentiation during lung development and disease. The 2-year grant, which runs from February 2025 to November 2026, aims to: 1) decipher HH's temporal control over differentiation in mouse lungs, 2) characterize HH-receiving cell...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,659,996 to the University of Southern California (USC) from April 1, 2025 to January 31, 2029. The funding supports research to investigate the role of the protein PDLIM2 in regulating alveolar macrophage function, which is critical for lung innate immunity, inflammation, and respiratory diseases. The research aims to elucidate the...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $480,990 to the University of Illinois for a research project focused on accelerating alveolar epithelial regeneration to treat acute respiratory distress syndrome (ARDS). The key objectives are to investigate the role of "aerocytes", a newly identified capillary endothelial cell population, in regulating alveolar...
This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $277,610.00 to Duke University to research the role of TP53 regulation in alveolar epithelial transitional cell state and the contribution of this transitional cell state to pulmonary fibrosis. The project aims to uncover the molecular mechanisms regulating alveolar epithelial cell states and determine the impact of the transitional cell state on pulmonary fibrosis,...
This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $797,845 to Vanderbilt University Medical Center to conduct research on reconceptualizing disease progression in pulmonary fibrosis. The key objectives are to: Fit and validate a Bayesian disease progression model to define the conserved, sequenced, and stage-specific progression in pulmonary fibrosis across physiological, anatomical, and biological domains. Test...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program provides $564,445 in funding to the University of Texas Health Science Center at Houston (UTHealth) to conduct research focused on targeting hypoxia-inducible factors (HIFs) for heart and lung disease. The research program consists of three complementary projects: 1) Exploring the upstream regulation of HIFs by prolyl hydroxylase domain enzymes...